875164-01-5 Usage
Uses
Used in Pharmaceutical Industry:
(8-METHYL-4-OXOQUINAZOLIN-3(4H)-YL)ACETIC ACID is used as an anti-inflammatory agent for its potential to treat various inflammatory diseases. It has shown promise in reducing inflammation and managing symptoms associated with these conditions.
Used in Pain Management:
In the field of pain management, (8-METHYL-4-OXOQUINAZOLIN-3(4H)-YL)ACETIC ACID is used as an analgesic for its potential to alleviate pain and discomfort in patients suffering from various conditions.
Used in Fever Reduction:
(8-METHYL-4-OXOQUINAZOLIN-3(4H)-YL)ACETIC ACID is used as an antipyretic to help reduce fever and associated symptoms in patients.
Used in Anticancer Applications:
In the oncology sector, (8-METHYL-4-OXOQUINAZOLIN-3(4H)-YL)ACETIC ACID is used as a potential anticancer agent. Research suggests that it may have inhibitory effects on certain cancer cell lines, making it a candidate for further investigation into its role in cancer treatment.
Used in Drug Development:
(8-METHYL-4-OXOQUINAZOLIN-3(4H)-YL)ACETIC ACID is used in the development of new drugs due to its diverse pharmacological properties. Its potential applications in various therapeutic areas make it a valuable compound for further research and development in the pharmaceutical industry.
Check Digit Verification of cas no
The CAS Registry Mumber 875164-01-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,5,1,6 and 4 respectively; the second part has 2 digits, 0 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 875164-01:
(8*8)+(7*7)+(6*5)+(5*1)+(4*6)+(3*4)+(2*0)+(1*1)=185
185 % 10 = 5
So 875164-01-5 is a valid CAS Registry Number.
875164-01-5Relevant academic research and scientific papers
Optimization of a Novel Quinazolinone-Based Series of Transient Receptor Potential A1 (TRPA1) Antagonists Demonstrating Potent in Vivo Activity
Schenkel, Laurie B.,Olivieri, Philip R.,Boezio, Alessandro A.,Deak, Holly L.,Emkey, Renee,Graceffa, Russell F.,Gunaydin, Hakan,Guzman-Perez, Angel,Lee, Josie H.,Teffera, Yohannes,Wang, Weiya,Youngblood, Beth D.,Yu, Violeta L.,Zhang, Maosheng,Gavva, Narender R.,Lehto, Sonya G.,Geuns-Meyer, Stephanie
, p. 2794 - 2809 (2016/04/10)
There has been significant interest in developing a transient receptor potential A1 (TRPA1) antagonist for the treatment of pain due to a wealth of data implicating its role in pain pathways. Despite this, identification of a potent small molecule tool possessing pharmacokinetic properties allowing for robust in vivo target coverage has been challenging. Here we describe the optimization of a potent, selective series of quinazolinone-based TRPA1 antagonists. High-throughput screening identified 4, which possessed promising potency and selectivity. A strategy focused on optimizing potency while increasing polarity in order to improve intrinisic clearance culminated with the discovery of purinone 27 (AM-0902), which is a potent, selective antagonist of TRPA1 with pharmacokinetic properties allowing for >30-fold coverage of the rat TRPA1 IC50 in vivo. Compound 27 demonstrated dose-dependent inhibition of AITC-induced flinching in rats, validating its utility as a tool for interrogating the role of TRPA1 in in vivo pain models.
